Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study
Table 1
Serological, clinical, and other diagnostic findings in patients with first-time determined positive serum ANA and musculoskeletal complaints.
Diagnoses in patients with positive ANA
Age ± SD (years)
ESR ± SD (mm)
SCL-70/ACA ()
CRP ± SD (mg/l)
ANA (titer) median
ECHO- PAP ≥ 30 mmHg (, %)
FEV1% VC
VC
TLCO/VA ≤ 70% ()
RP ()
Mean HAQ score ± SD
Mean VAS ± SD (mm)
Physician Global Assessment Scale 0–10
Patient Global Assessment scale 0–10
RA
51.9 ± 13.9
20.1 ± 24.1
0 (0%)
6.9 ± 12.8
1 : 320
2 (6.25%)
109.2 ± 9.9
98.7 ± 15.9
8 (25%)
9 (28%)
1.0 ± 0.8
53.1 ± 28.6
5.5 ± 2.1
6.0 ± 2.5
UCTD
54 ± 14
15 ± 13
0 (0%)
4.6 ± 3.8
1 : 320
3 (10%)
111.0 ± 15.6
88.5 ± 15.4
9 (30%)
2 (7%)
0.3 ± 0.3
33.5 ± 26.4
3.0 ± 2.0
3.5 ± 2.3
SSc
56 ± 13.1
18.5 ± 19.9
11 (100%)
5,8 ± 7.8
1 : 10240
3 (27%)
109.6 ± 9.7
94.0 ± 13.7
2 (18%)
9 (82%)
0.5 ± 0.6
42 ± 31.2
4.6 ± 2.6
5.2 ± 3.17
SjS
45 ± 13
19 ± 16
0 (0%)
8,2 ± 14.1
1 : 320
0 (0%)
105.8 ± 6.8
86.7 ± 17.0
1 (14%)
1 (14%)
0.7 ± 0.7
37.8 ± 30.8
5.0 ± 2.8
5.1 ± 2.9
Findings are shown as mean with exception to ANA titers that are indicated as median. ECHO, FEV1% VC, TLCO VA, and RP are indicated as %. RA: rheumatoid arthritis; UCTD: undifferentiated connective tissue diseases; SSc: systemic sclerosis; SjS: Sjörgen’s syndrome; ESR: erythrocyte sedimentation rate; ACA: anti-SCL-70 or anti-centromere antibodies; CRP: C-reactive protein.
